Correction

To cite this article: (2024) Correction, Journal of Medical Economics, 27:1, 165-166, DOI: 10.1080/13696998.2024.2305006

To link to this article:  https://doi.org/10.1080/13696998.2024.2305006

© 2024 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group

Published online: 13 Jan 2024.

Submit your article to this journal

Article views: 448

View related articles

View Crossmark data
Correction

Article title: Translating the efficacy of dapagliflozin in chronic kidney disease to lower healthcare resource utilization and costs: a medical care cost offset analysis


Journal: Journal of Medical Economics

Bibliometrics: Volume 26, Number 1, pages 1407–1416

DOI: https://doi.org/10.1080/13696998.2023.2264715

The above mentioned article was first published online with the errors outlined below. These errors are now been corrected in Abstract, Table 2, and Results section to ensure alignment between the in-text results and Table 2, and article has been re-published online.

- The event incidence for hospitalisation for heart failure (HHF) associated with standard therapy in Table 2 is currently stated as 2,684, whereas the correct figure is 4,684, which is stated in the text and the abstract. This is in line with the incremental difference calculation in Table 2 whereby 2,370 (dapagliflozin plus standard therapy) - 4,684 (standard therapy) = -2,314.
- The event incidence for standard therapy in AKI in Table 2 should be edited from 5,821 to 5,819, which is in line with the incremental difference calculation and aligns with the stated incidence for AKI in the results and abstract.
- There is a minor discrepancy for incidence for ACM due to rounding in the cost offset model. In Table 2 the event incidence for standard therapy states 8,875, whereas the in-text results state 8,874 and 2,491, hence, the in-text results have been amended accordingly.

Abstract

Results: Patients treated with dapagliflozin plus standard therapy experienced fewer incidents of ESKD (7,221 vs 10,767; number needed to treat, NNT: 28), HHF (2,370 vs 4,684; NNT: 43), AKI (4,110 vs. 5,819; NNT: 58), and ACM (6,383 vs 8,875; NNT: 40) per 100,000 treated patients versus those treated with standard therapy alone. Across 31 countries/regions, reductions in clinical events were associated with a 33% reduction in total costs, or a cumulative mean medical care cost offset of $264 million per 100,000 patients over 3 years.

Results

Over a 3-year period, 2,492 fewer deaths from any cause were expected per 100,000 patients treated with dapagliflozin in addition to standard therapy (dapagliflozin: 6,383, standard therapy only: 8,875; NNT: 40; Table 2) - an estimated 28.1% reduction in ACM. Treatment with dapagliflozin was also associated with lower rates of non-fatal events, leading to substantial medical care cost offsets to treatment with dapagliflozin versus those treated with standard therapy alone in the considered countries/regions.
### Table 2. Clinical outcomes per 100,000 patients over a 3-year time horizon, stratified by treatment received in the DAPA-CKD trial.

<table>
<thead>
<tr>
<th>Outcome</th>
<th>Dapagliflozin plus standard therapy</th>
<th>Standard therapy</th>
<th>Incremental</th>
<th>Number needed to treat</th>
</tr>
</thead>
<tbody>
<tr>
<td>ESKD</td>
<td>7,221</td>
<td>10,767</td>
<td>−3,546</td>
<td>28</td>
</tr>
<tr>
<td>HHF</td>
<td>2,370</td>
<td>4,684</td>
<td>−2,314</td>
<td>43</td>
</tr>
<tr>
<td>AKI</td>
<td>4,110</td>
<td>5,819</td>
<td>−1,709</td>
<td>58</td>
</tr>
<tr>
<td>All-cause mortality</td>
<td>6,383</td>
<td>8,875</td>
<td>−2,492</td>
<td>40</td>
</tr>
</tbody>
</table>

Abbreviations. AKI, Acute kidney injury; ESKD, End-stage kidney disease; HHF, Hospitalization for heart failure.